 SIOUX FALLS, S.D.--BUSINESS WIRE--- BCYP COVID19--SAB Biotherapeutics SAB, a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibody therapeutics, today announced the publication of in vitro data showing that SAB-185, the companys therapeutic candidate for the treatment of COVID-19 virus infections, demonstrated effective neutralization against SARS-CoV-2 virus strains containing the genetic substitutio 